Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic [electronic resource]
Producer: 20180511Description: 5339-5348 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Agents -- administration & dosage
- Carbamates -- administration & dosage
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Drug Monitoring
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Mice
- Molecular Targeted Therapy
- Mutation
- Neoplasm Staging
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Sulfonamides -- administration & dosage
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.